10 Best Organ Transplant and Diagnosis Stocks To Buy Now

2. Abbott Laboratories (NYSE:ABT)

Market Cap as of August 1: $191.65 Billion

Hedge Funds Holding Stakes: 62

Given its rich history in transplant diagnostics, Abbott Laboratories (NYSE:ABT) is one of the 10 best organ transplant and diagnosis stocks to buy now. The company has made a name for itself in developing cutting-edge technologies that enhance organ transplant outcomes. Consequently, Abbott Laboratories (NYSE:ABT) remains the go-to company for healthcare providers in transplant medicine across the globe.

Abbott Laboratories (NYSE:ABT) offers transplant assays that assist medical professionals in choosing the best treatment options for patients to prevent adverse reactions and kidney damage, reduce the risk of organ rejection, and keep track of patients not following their treatment plans. While Abbott Laboratories (NYSE:ABT) is down by 4% for the year, it generated $40.1 billion in sales in 2023.

According to the Insider Monkey database, 62 out of 920 hedge funds tracked held stakes in Abbott Laboratories (NYSE:ABT) as of the end of Q1 2024.

In its Q2 2024 investor letter, Diamond Hill Select Strategy commented on Abbott Laboratories (NYSE:ABT) as follows:

“Abbott Laboratories (NYSE:ABT) is a diversified health care company with an extensive portfolio that spans medical devices, pharmaceuticals, nutritionals and diagnostics. With a substantial portion of its revenues generated internationally, emerging markets contribute about 40% of overall sales. We have always liked Abbott’s diverse mix of businesses and its fundamental growth prospects. The management team has consistently demonstrated skill in capital allocation, highlighted by strategic divestitures such as the European generic business in 2014, and significant acquisitions like St. Jude in 2016.”